AAminove
Back to library

Liraglutide

Human RCTApproved medicine

Also known as: Victoza, Saxenda

GLP-1 / incretinType 2 diabetesWeight management

Community-reported ranges are anecdotal and not clinically validated. Evidence grade shown reflects the strength of available human data. Not a prescription. Legal status varies by country and changes over time; verify locally.

Overview

A daily GLP-1 receptor agonist approved for type 2 diabetes and weight management. Well evidenced but largely superseded by weekly agents.

Mechanism

GLP-1 receptor agonism improving glycaemic control and reducing appetite.

Evidence

Human RCTWhat does this mean?

Strong: LEAD and SCALE phase 3 programmes; regulatory approval.

Community-reported information

Prescription medicine dosed per label and clinician.

General information only, not tailored to you and not a recommendation. Some regions withhold this entirely.

Half-life

~13 hours (once-daily dosing)

Storage

Refrigerate before first use; per label in use.

Commonly reported side effects

  • Nausea
  • Diarrhoea
  • Headache
  • Injection-site reactions

Legal status by region

  • USFDA-approved prescription medicine.
  • GBMHRA-licensed; prescription only.

Legal status changes over time; verify locally before relying on this.

Citations